Latest news with #DavidRosen
Globe and Mail
02-05-2025
- Business
- Globe and Mail
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the 'Company'), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company's common stock with an exercise price of $12.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on May 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on May 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. A Phase 3 trial of Descartes-08 in patients with generalized myasthenia gravis has received written agreement from the FDA under the Special Protocol Assessment process. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter. Contact Information: Investor Contact: Megan LeDuc Associate Director, Investor Relations Media Contact: David Rosen Argot Partners
Daily Mail
28-04-2025
- Health
- Daily Mail
Doctor reveals reason why everyone should be sleeping naked - it has surprising health benefits
A top doctor has revealed the surprising benefits to sleeping naked—and why everyone should be doing it. Sleeping in the buff could give you a better night's kip, reduce the risk of genital infections, boost male fertility and lead to a stronger connection with your partner. According to sleep medicine physician Dr David Rosen, the benefits lie with the cooling effect of ditching pyjamas. A cooler body temperature is needed at night to help achieve adequate balance of naturally-produced hormones that promote sleep, such as meatonin. If skin temperature is too high—which usually happens in a room above 21 degrees celcius— this can disrupt hormones to the extent it prevents us from reaching the deepest, most restorative levels of sleep. 'Keeping cool at night is a simple way to improve sleep quality,' said Dr Rosen, who works with the American Academy of Sleep Medicine. 'For those who prefer to sleep with a thick and warm comforter, sleeping naked is a good way to counterbalance that extra warmth.' Another benefit of sleeping in the nude is a reduced risk of a nasty vaginal yeast infections, otherwise known as thrush. One night of poor sleep causes your brain to function at a slower rate, impacting concentration. Puffy eyes are also common, along with a difficulty to stay alert and the tendency to react negatively to situations you wouldn't normally do so The fungus can thrive in warm, moist environments, such as pyjama bottoms, as the fabric interacts with the gentials, according to a medical report co-authored by Dr Rosen. The infection—an overgrowth of Candida yeast— causes pain and itching, and is often due to tight underwear or other clothing. Aring the intimate area helps to stop fungus from thriving. Men should also avoid tight-fighting garments in bed, as it could impact male fertility, according to Dr Rosen. Research suggests that snug briefs could increase the temperature of the scrotum, which can decrease sperm vitality and count. There is evidence that a cool scrotum directly impacts sperm motility, helping it to reach the egg for fertilisation. Couples could also benefit as it may increase feelings of connection due to skin-to-skin contact, which leads to the release of the 'love' hormone oxytocin. Studies show that the chemical can reduce stress, as well as boost feelings of happiness and contentment. It follows a 2024 survey of 20,000 people worldwide that revealed 20 per cent of Britons choose to sleep in the nude. While seven in ten women opt to wear pyjamas to bed, men are more likely to sleep in their underwear or nothing at all, with more than 22 per cent choosing to sleep naked. This is most prevalent among those 50-years-old and above, with more than 32 per cent of this age group opting to sleep without clothes, according to research by bed and mattress brand Sealy.
Yahoo
04-04-2025
- Business
- Yahoo
Gold prices soar to record high amid market crash fears
CHICOPEE, Mass. (WWLP) – After a stock market crash, gold might be your next investment. Gold hit an all-time high this week, reaching a record of over $3,100, that`s about 40% higher than a year ago. This is the strongest quarter for gold since 1986 partly due to fears around Trump's tariffs which have triggered instability. Gold traders say it then leaves investors feeling anxious about the economy and looking to safe-haven assets. Unlike stocks or bonds, gold doesn't pay any dividends or interest and doesn't generate any ongoing returns. David Rosen, a gold trader in Springfield told 22News, 'It's whether you're selling gold or buying gold, it's a good investment and the same thing holds for gold jewelry. When you own a piece of gold jewelry, you own gold. So unlike a used car that will depreciate over ten years and be worth nothing. Gold jewelry is always worth the gold.' These investors are also not just buying up gold jewelry, coins, or bars but also pouring their money into gold-exchange traded funds. This allows people to invest in gold without physically owning it. $6.8 Billion flowed into North American gold ETFs two months ago according to the World Gold Council. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
25-02-2025
- Business
- Yahoo
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at The webcast will be archived and available for replay for 90 days after the call via the Rigel website. About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit Contact for Investors & Media: Investors:Rigel Pharmaceuticals, Inc.650.624.1232ir@ Media:David Rosen Argot Partners Phone: 646.461.6387Email: View original content to download multimedia: SOURCE Rigel Pharmaceuticals, Inc.
